830346-49-1 Usage
Description
Carbamic acid, N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester, also known as Elagolix Methoxy-d3 Sodium Salt (E501024), is a labeled analogue of Elagolix (E50108). It is a novel uracil phenylethylamine that acts as a potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonist.
Uses
Used in Pharmaceutical Industry:
Carbamic acid, N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester is used as an intermediate in the synthesis of Elagolix Methoxy-d3 Sodium Salt (E501024). Carbamic acid, N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester is a potent hGnRH-R antagonist, which has potential applications in the development of treatments for various hormonal disorders and conditions related to the gonadotropin-releasing hormone receptor.
Check Digit Verification of cas no
The CAS Registry Mumber 830346-49-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,3,0,3,4 and 6 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 830346-49:
(8*8)+(7*3)+(6*0)+(5*3)+(4*4)+(3*6)+(2*4)+(1*9)=151
151 % 10 = 1
So 830346-49-1 is a valid CAS Registry Number.
InChI:InChI=1/C26H26BrF4N3O4/c1-15-21(27)22(35)34(14-20(16-9-6-5-7-10-16)32-23(36)38-25(2,3)4)24(37)33(15)13-17-18(26(29,30)31)11-8-12-19(17)28/h5-12,20H,13-14H2,1-4H3,(H,32,36)/t20-/m0/s1
830346-49-1Relevant articles and documents
Oxagolix intermediate, and preparation method and application thereof
-
, (2021/02/10)
The invention provides a preparation method of a novel oxagolix important intermediate compound 1, and also provides two novel intermediate compounds 5 and 6. By starting from the novel intermediate compound 5, the five-step synthesis in the prior art is
PROCESS FOR THE SYNTHESIS OF THE SODIUM SALT OF 4-[[(LR)-2-[5-(2-FLUORO-3-METHOXYPHENYL)-3-[[2-FLUORO-6-(TRIFLUOROMETHYL)-PHENYL]METHYL]-3,6-DIHYDRO-4-METHYL-2,6-DIOXO-L(2H)-PYRIMIDINYL]-L- PHENYLETHYL]AMINO]-BUTANOIC ACID (ELAGOLIX SODIUM SALT) AND INTER
-
Page/Page column 12, (2021/03/13)
The present invention relates to a process for the preparation of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-l(2H)-pyrimidinyl]-l-phenylethyl]-amino]-butanoic a
PROCESS FOR THE PREPARATION OF ELAGOLIX SODIUM AND INTERMEDIATES THEREOF
-
Page/Page column 25, (2020/10/17)
The present invention relates to compounds of Formula A, isomers, polymorphs and process of preparation thereof, wherein, S is a pharmaceutically acceptable salt, R is selected from hydrogen or C1-C3 alkyl group substituted with Rsu